Почетна › Многи мијелом › Висконсин › Milwaukee
Kliničke studije za Многи мијелом u gradu Milwaukee, WI
23 studija za Многи мијелом traži učesnike na lokacijama u gradu Milwaukee i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Тражи се учесникФаза 3
- Medical College of Wisconsin, Milwaukee
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
Тражи се учесникФаза 2
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Тражи се учесникФаза 4
- Froedtert Memorial, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- Medical College Of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Тражи се учесникФаза 3
- Medical College of Wisconsin, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Тражи се учесникФаза 1/2
- Medical College of Wisconsin, Milwaukee
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Тражи се учесникФаза 3
- Research Site, Milwaukee
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Тражи се учесникФаза 3
- Medical College of Wisconsin, Milwaukee
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Тражи се учесникФаза 1/2
- Research Site, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Тражи се учесник
- Medical College of Wisconsin, Milwaukee
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Тражи се учесникФаза 3
- Research Site, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Тражи се учесникФаза 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- и још 4
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Тражи се учесникФаза 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- и још 13
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Тражи се учесникФаза 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Тражи се учесникФаза 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Тражи се учесникФаза 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Тражи се учесникФаза 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Тражи се учесникОпсервациона студија
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Studije za Многи мијелом u drugim gradovima
- New York City, NY59 студија
- Boston, MA45 студија
- Atlanta, GA42 студија
- Houston, TX39 студија
- Durham, NC36 студија
- Nashville, TN31 студија
- Denver, CO26 студија
- St. Louis, MO26 студија
- Rochester, MN25 студија
- Columbus, OH25 студија
- Chicago, IL24 студија
- Baldwin Park, CA23 студија
Ostale studije u gradu Milwaukee
- Рак (све врсте)24 студија
- Рак дојке22 студија
- Немалоклетни карцином плућа21 студија
- Рак плућа21 студија
- Не-Ходжкинов лимфом19 студија
- Фоликуларни лимфом19 студија
- Рак простате19 студија
- Akutna mijeloidna leukemija18 студија
- Рак панкреаса18 студија
- Рак јајника17 студија
- Difuzni veliki B-ćelijski limfom17 студија
- Беркитов лимфом16 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.